Literature DB >> 2395886

2,3,7,8-Tetrachlorodibenzo-p-dioxin causes an extensive alteration of 17 beta-estradiol metabolism in MCF-7 breast tumor cells.

D C Spink1, D W Lincoln, H W Dickerman, J F Gierthy.   

Abstract

MCF-7 breast tumor cells form multicellular foci in vitro when supplemented with 17 beta-estradiol (E2). In the presence of E2 and the aryl hydrocarbon-receptor agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), MCF-7 cells grow to confluence but do not form foci. To investigate the role of E2 metabolism in this antiestrogenic effect of TCDD, analyses were performed by capillary GC/MS. The results revealed that pretreatment of MCF-7 cultures with TCDD (10 nM) rapidly depletes E2. In untreated cultures supplemented with 10 nM E2, the concentration of free E2 decreased to 4 nM in the first 12 hr, followed by a slower rate of decline. After 3 days most E2 in the medium was in conjugated form(s); 1.7 nM was present as free E2, and 2.9 nM was released by treatment with glucuronidase/sulfatase. In TCDD-treated cultures, E2 declined to 290 pM in 12 hr and after 2 days was not detected (less than 100 pM) either as free steroid or after treatment with glucuronidase/sulfatase. Intracellular E2 and estrone were likewise depleted by pretreatment with TCDD. Microsomes from TCDD-treated cells showed highly elevated aryl hydrocarbon-hydroxylase activity and catalyzed hydroxylations of E2 at C-2, C-4, C-15 alpha, and C-6 alpha with a combined rate of 0.85 nmol/min per nmol of cytochrome P-450 at saturating E2. These results suggest that depletion of E2 by enhanced metabolism accounts for the antiestrogenic activity of TCDD in MCF-7 cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2395886      PMCID: PMC54649          DOI: 10.1073/pnas.87.17.6917

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  48 in total

1.  Relation between cytochrome P450IA1 expression and estrogen receptor content of human breast cancer cells.

Authors:  P J Vickers; M J Dufresne; K H Cowan
Journal:  Mol Endocrinol       Date:  1989-01

Review 2.  P450 genes: structure, evolution, and regulation.

Authors:  D W Nebert; F J Gonzalez
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

3.  Suppression of estrogen-regulated extracellular tissue plasminogen activator activity of MCF-7 cells by 2,3,7,8-tetrachlorodibenzo-p-dioxin.

Authors:  J F Gierthy; D W Lincoln; M B Gillespie; J I Seeger; H L Martinez; H W Dickerman; S A Kumar
Journal:  Cancer Res       Date:  1987-12-01       Impact factor: 12.701

4.  Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on hepatic and uterine estrogen receptor levels in rats.

Authors:  M Romkes; J Piskorska-Pliszczynska; S Safe
Journal:  Toxicol Appl Pharmacol       Date:  1987-02       Impact factor: 4.219

5.  Activation and irreversible binding of regiospecifically labeled catechol estrogen by rat liver microsomes: evidence for differential cytochrome P-450 catalyzed oxidations.

Authors:  P H Jellinck; J Fishman
Journal:  Biochemistry       Date:  1988-08-09       Impact factor: 3.162

6.  Biological effects and morphological responses to estriol, estriol-3-sulfate, estriol-17-sulfate and tamoxifen in a tamoxifen-resistant cell line (R-27) derived from MCF-7 human breast cancer cells.

Authors:  J R Pasqualini; C Gelly; F Lecerf
Journal:  Eur J Cancer Clin Oncol       Date:  1986-12

7.  Estrogens and growth factors induce the mRNA of the 52K-pro-cathepsin-D secreted by breast cancer cells.

Authors:  V Cavailles; P Augereau; M Garcia; H Rochefort
Journal:  Nucleic Acids Res       Date:  1988-03-25       Impact factor: 16.971

8.  Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens.

Authors:  B S Katzenellenbogen; K L Kendra; M J Norman; Y Berthois
Journal:  Cancer Res       Date:  1987-08-15       Impact factor: 12.701

9.  A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.

Authors:  B Fisher; J Costantino; C Redmond; R Poisson; D Bowman; J Couture; N V Dimitrov; N Wolmark; D L Wickerham; E R Fisher
Journal:  N Engl J Med       Date:  1989-02-23       Impact factor: 91.245

10.  Metabolic fate of estradiol in human mammary cancer cells in culture: estrogen sulfate formation and cooperativity exhibited by estrogen sulfotransferase.

Authors:  J B Adams; N S Phillips; R Hall
Journal:  Mol Cell Endocrinol       Date:  1988-08       Impact factor: 4.102

View more
  28 in total

1.  Antiestrogenic activity of anthropogenic and natural chemicals.

Authors:  J M Navas; H Segner
Journal:  Environ Sci Pollut Res Int       Date:  1998       Impact factor: 4.223

2.  Cytochrome P450-mediated 17beta-estradiol metabolism in zebrafish (Danio rerio).

Authors:  Marcus L Scornaienchi; Cammi Thornton; Kristine L Willett; Joanna Y Wilson
Journal:  J Endocrinol       Date:  2010-06-03       Impact factor: 4.286

Review 3.  Endocrine disrupting chemicals targeting estrogen receptor signaling: identification and mechanisms of action.

Authors:  Erin K Shanle; Wei Xu
Journal:  Chem Res Toxicol       Date:  2010-11-05       Impact factor: 3.739

Review 4.  Adipose Tissue as a Site of Toxin Accumulation.

Authors:  Erin Jackson; Robin Shoemaker; Nika Larian; Lisa Cassis
Journal:  Compr Physiol       Date:  2017-09-12       Impact factor: 9.090

5.  Effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on growth factor expression in the human breast cancer cell line MCF-7.

Authors:  C Vogel; J Abel
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

6.  Long-term estrogen exposure promotes carcinogen bioactivation, induces persistent changes in gene expression, and enhances the tumorigenicity of MCF-7 human breast cancer cells.

Authors:  Barbara C Spink; James A Bennett; Brian T Pentecost; Nicole Lostritto; Neal A Englert; Geoffrey K Benn; Angela K Goodenough; Robert J Turesky; David C Spink
Journal:  Toxicol Appl Pharmacol       Date:  2009-07-18       Impact factor: 4.219

Review 7.  Role of the aryl hydrocarbon receptor in carcinogenesis and potential as a drug target.

Authors:  Stephen Safe; Syng-Ook Lee; Un-Ho Jin
Journal:  Toxicol Sci       Date:  2013-06-14       Impact factor: 4.849

8.  Induction of CYP1A1 and CYP1B1 by benzo(k)fluoranthene and benzo(a)pyrene in T-47D human breast cancer cells: roles of PAH interactions and PAH metabolites.

Authors:  David C Spink; Susan J Wu; Barbara C Spink; Mirza M Hussain; Dilip D Vakharia; Brian T Pentecost; Laurence S Kaminsky
Journal:  Toxicol Appl Pharmacol       Date:  2007-09-05       Impact factor: 4.219

Review 9.  The aryl hydrocarbon receptor complex and the control of gene expression.

Authors:  Timothy V Beischlag; J Luis Morales; Brett D Hollingshead; Gary H Perdew
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2008       Impact factor: 1.807

10.  Role of GAC63 in transcriptional activation mediated by the aryl hydrocarbon receptor.

Authors:  Yong-Heng Chen; Timothy V Beischlag; Jeong Hoon Kim; Gary H Perdew; Michael R Stallcup
Journal:  J Biol Chem       Date:  2006-03-02       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.